Deucravacitinib’s Safety and Efficacy Holds in Five-Year PsO Study
Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed consistent safety and efficacy in patients with in moderate-to-severe plaque psoriasis for up to five years, new research shows. In psoriasis patients who were treated continuously with deucravacitinib, clinical response rates were maintained from Year 1 to Year 5, including Psoriasis Area and Severity Index (PASI) 75, PASI 90 […]